Scientists recently published a review article examining the supplement L-carnitine and a common liver condition called MASLD. MASLD, which involves fat buildup in the liver, affects over a third of people globally and is linked to higher risks for heart and kidney disease. The review did not study new patients but instead summarized existing lab and animal research on how L-carnitine works.
The authors explain that, in theory, L-carnitine could help the liver by improving how it burns fat, reducing inflammation, and protecting liver cells. These are proposed biological mechanisms based on earlier research, not proven results from treating people with the supplement.
It is very important to understand that this article is a review of ideas and early science. It does not provide any data from human clinical trials, so we do not know if L-carnitine actually helps patients with MASLD, what dose to use, or if it is safe for this purpose. Readers should see this as an explanation of early scientific concepts, not as evidence for using this supplement. More research with people is needed to test these ideas.